Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On January 8, 2010, the Administrators of the Deferred Investment Award Plan notified the Company of an increase in share interests for specific individuals following the re-investment of the dividend paid on January 7, 2010. The transaction price was £12.98 per share. The specific increases were:
- Mr E J Gray: 274.93 shares
- Mr S A Hussain: 492.80 shares
- Mr D S Redfern: 217.50 shares
- Ms C Thomas: 135.94 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is strictly a compliance notification regarding director shareholdings.
Investor Verification Checklist
- Verify the dividend payment date of January 7, 2010, and the reinvestment price of £12.98 per share.
- Confirm the updated shareholdings for Mr E J Gray, Mr S A Hussain, Mr D S Redfern, and Ms C Thomas.
- Review the full Deferred Investment Award Plan rules to understand the mechanics of the dividend reinvestment.